Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Short term Debt: 2020-2022

Historic Short term Debt for Mirum Pharmaceuticals (MIRM) over the last 3 years, with Dec 2022 value amounting to $1.1 million.

  • Mirum Pharmaceuticals' Short term Debt fell 45.39% to $1.1 million in Q1 2023 from the same period last year, while for Mar 2023 it was $1.1 million, marking a year-over-year decrease of 45.39%. This contributed to the annual value of $1.1 million for FY2022, which is 45.39% down from last year.
  • Mirum Pharmaceuticals' Short term Debt amounted to $1.1 million in FY2022, which was down 45.39% from $2.0 million recorded in FY2021.
  • Over the past 5 years, Mirum Pharmaceuticals' Short term Debt peaked at $2.0 million during FY2021, and registered a low of $1.1 million during FY2022.
  • Its 3-year average for Short term Debt is $1.4 million, with a median of $1.3 million in 2020.
  • Its Short term Debt has fluctuated over the past 5 years, first spiked by 57.91% in 2021, then slumped by 45.39% in 2022.
  • Yearly analysis of 3 years shows Mirum Pharmaceuticals' Short term Debt stood at $1.3 million in 2020, then skyrocketed by 57.91% to $2.0 million in 2021, then crashed by 45.39% to $1.1 million in 2022.